Results 51 to 60 of about 266,081 (333)

Dosimetric analysis of local failures in skull-base chordoma and chondrosarcoma following pencil beam scanning proton therapy

Radiation Oncology, 2020
Background Despite combined modality treatment involving surgery and radiotherapy, a relevant proportion of skull-base chordoma and chondrosarcoma patients develop a local recurrence (LR).
Lucas Basler, Robert Poel, Christina Schröder, Alessandra Bolsi, Antony Lomax, Stephanie Tanadini-Lang, Matthias Guckenberger, Damien C. Weber   +7 more
doaj   +1 more source

Verification of an independent dose calculation method for portal-specific QA of proton and carbon ion beams

Radiation Medicine and Protection, 2022
Objective: To verify the accuracy of an independent dose calculation method, as incorporated into an in-house developed treatment planning system (TPS), for performing quality assurance of dose distributions delivered to a water phantom planned by a ...
Michael F. Moyers, Qianxia Wang, Yu Deng, Hongliang Chen, Zhi Chen, Xiaoli Liu, Nicki Schlegel, Jie Li, Zhuangming Shen, James Lin, Pablo Yepes   +10 more
doaj   +1 more source

Molecular characterisation of human penile carcinoma and generation of paired epithelial primary cell lines

Molecular Oncology, EarlyView.
Generation of two normal and tumour (cancerous) paired human cell lines using an established tissue culture technique and their characterisation is described. Cell lines were characterised at cellular, protein, chromosome and gene expression levels and for HPV status.
Simon Broad, Mahmood Hachim, Tom Bertin, Karolina Penderecka, Rifat Hamoudi, Saif Khan, Rui Henrique, Natalie Bergmoser, Manit Arya, Kalle Sipila, Matteo Vietri Rudan, Asif Muneer, Aamir Ahmed   +12 more
wiley   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

Clinical outcomes of image-guided proton therapy for histologically confirmed stage I non-small cell lung cancer

Radiation Oncology, 2018
Background Two prospective phase II trials were designed to assess the efficacy and safety of image-guided proton therapy (IGPT) for either medically inoperable or operable stage I non-small cell lung cancer (NSCLC). The present study reports the interim
Koichiro Nakajima, Hiromitsu Iwata, Hiroyuki Ogino, Yukiko Hattori, Shingo Hashimoto, Toshiyuki Toshito, Kensuke Hayashi, Kenji Akita, Fumiya Baba, Katsumi Nakamae, Jun-etsu Mizoe, Yuta Shibamoto   +11 more
doaj   +1 more source

Clinical consequences of relative biological effectiveness variations in proton radiotherapy of the prostate, brain and liver [PDF]

, 2013
Proton relative biological effectiveness (RBE) is known to depend on the (alpha/beta)(x) of irradiated tissues, with evidence of similar to 60% variation over (alpha/beta)(x) values from 1-10 Gy.
Carabe, Alejandro, Espana Palomares, Samuel, Grassberger, Clemens, Paganetti, Harald   +3 more
core   +1 more source

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

Molecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien   +35 more
wiley   +1 more source

Proton beam therapy achieves excellent local control for recurrent epithelial ovarian cancer: a single-center retrospective study

Journal of Ovarian Research
Background Previous studies have demonstrated the benefit of radiation therapy for patients with recurrent epithelial ovarian cancer; however, the effects of proton beam therapy in these patients remain unelucidated.
Yuta Endo, Yoshiaki Takagawa, Yuki Yoshimoto, Masanori Machida, Yuntao Dai, Yusuke Azami, Ichiro Seto, Kanako Takayama, Motohisa Suzuki, Tatsuhiko Nakasato, Yasuhiro Kikuchi, Takahiro Kato, Akiko Yamaguchi, Shu Soeda, Keiya Fujimori, Masao Murakami   +15 more
doaj   +1 more source

Proton beam radiotherapy in the management of uveal melanoma: clinical experience in Scotland [PDF]

, 2008
<p>Aim: To evaluate proton-beam radiotherapy (PBRT) in the management of uveal melanoma in Scotland.</p> <p>Methods: A retrospective review was undertaken on all patients receiving PBRT for uveal melanoma (1994–2005).
Aziz, S., Kacperek, A., Kemp, E., McConnachie, A., Taylor, A.   +4 more
core   +3 more sources

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

Molecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone, James Dunford, Eleanor Calcutt, Vicki Gamble, Filiz Senbabaoglu Aksu, Lorena Ligammari, Georgina Wherry, Giorgia Gaeta, John C. Christianson, Adrienne M. Flanagan, Udo Oppermann, Adam P. Cribbs   +11 more
wiley   +1 more source